WebNov 8, 2015 · This report provides comprehensive information on the current therapeutic developmental pipeline of Incanthera Ltd.’s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. WebSnapshot. Incanthera says its interim results show strong financial control through the six-month period. Incanthera looking at big opportunity as Sol impresses in tests. Incanthera present results of first full year as public company on AQSE. Open Deep dive.
incanthera
WebIncanthera Ltd (Incanthera) is a biopharmaceutical company that discovers and develops therapeutic products for the treatment of cancer. The companys drug candidates under development include ICT2588, a vascular disrupting agent, based on the tumor-blasting technology; and ICT03 Es5, a targeted bioreductive agent; which are targeted at ... WebContact Who is Incanthera Headquarters 76 King St, Manchester, England, M2 4NH, United Kingdom Phone Number +44 1618175005 Website www.incanthera.com Revenue <$5M … biotechnology university in malaysia
Incanthera - Crunchbase Company Profile & Funding
WebMore for INCANTHERA PLC (11026926) Registered office address 76 King Street, Manchester, England, M2 4NH . Company status Active Company type Public limited Company Incorporated on 23 October 2024. Accounts. Next accounts made up to 31 March 2024 due by 30 September 2024 ... WebIncanthera Ltd. develops cancer treatment drugs. Its ICT-2588 is a lead compound that is activated within solid tumours by a specific WebApr 8, 2024 · Focused on the generation of new anticancer prodrugs, the ICT-DTC has been created following a major £2m investment by ICT spin-out company Incanthera Ltd. We are now looking for applications ... biotechnology upsc civilsdaily